H.B. Fuller Outlook Remains Beatable With Pricing Realization as Swing Factor, UBS Says

MT Newswires Live06-27

H.B. Fuller's (FUL) 2026 outlook remains conservative and beatable, although the planned acquisition of Advanced Medical Solutions is expected to weigh on the stock's valuation in the near term because of higher leverage, UBS said in a note emailed Friday.

The brokerage said it expects pricing realization likely to determine whether the company exceeds the upper end of its outlook.

"We continue to see the 2H26 outlook for FUL as conservative and beatable," UBS said. "We expect the acquisition of AMS to be a headwind to FUL's trading multiple in the short term," it added.

UBS cut its price target to $69 from $71 and maintained its neutral rating.

Price: 61.31, Change: -0.64, Percent Change: -1.03

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment